Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal

Aurobindo is betting big, buying certain portions of Sandoz’s US portfolio in a deal potentially worth $1bn. The acquisition positions the Indian firm in the top league in the overall US generics space by Rx and also segments like dermatology, but much could depend on how effectively Aurobindo delivers on value creation potential amid ongoing price pressures.

Big money
AUROBINDO HAS SEALED THE LARGEST OUTBOUND M&A DEAL BY AN INDIAN PHARMA FIRM • Source: Shutterstock

Aurobindo Pharma Ltd.'s acquisition of Sandoz International GMBH’s US dermatology business and generic US oral solids portfolio in a deal worth around $1bn will potentially trigger a significant shift in competitive dynamics in a market already under significant pricing pressure.

The deal, which represents the largest out-bound M&A transaction by an Indian pharma company, will catapult Aurobindo to second position...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip